(2021). Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.
Chicago Style (17th ed.) CitationRivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. 2021.
MLA (8th ed.) CitationRivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. 2021.
Warning: These citations may not always be 100% accurate.